Last Updated : April 5, 2018
Details
FilesGeneric Name:
guselkumab
Project Status:
Complete
Therapeutic Area:
Psoriasis, moderate to severe plaque
Manufacturer:
Janssen Inc.
Call for patient/clinician input open:
Brand Name:
Tremfya
Project Line:
Reimbursement Review
Project Number:
SR0530-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Psoriasis, moderate to severe plaque
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
Key Milestones2 | |
|---|---|
| Call for patient input posted | July 27, 2017 |
| Patient group input closed | September 18, 2017 |
Clarification: - Patient input submission received | |
| Patient input summary sent for review to patient input groups | September 22, 2017 |
| Patient group comments on input summary closed | September 29, 2017 |
Clarification: - Patient input summary feedback received | |
| Submission received | August 25, 2017 |
| Submission accepted for review | September 11, 2017 |
| Review initiated | September 12, 2017 |
| Draft CDR review report(s) sent to applicant | November 24, 2017 |
| Comments from applicant on draft CDR review report(s) received | December 05, 2017 |
| Redaction requests from applicant on draft CDR review report(s) received | December 12, 2017 |
| CDR review team's comments on draft CDR review report(s) sent to applicant | January 05, 2018 |
| Canadian Drug Expert Committee (CDEC) meeting | January 17, 2018 |
| CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plans | January 30, 2018 |
| Embargo period ended and validation of redacted CDR review report(s) received | February 13, 2018 |
| CDEC Final Recommendation issued to applicant and drug plans | February 21, 2018 |
| CDEC Final Recommendation posted | February 23, 2018 |
| Final CDR review report(s) and patient input posted | March 14, 2018 |
Files
Last Updated : April 5, 2018